Cilofexor is an FXR agonist which has been shown to improve cholestatic pattern of liver injury and transaminase abnormalities when used for PSC and NASH.24 Thus far in humans, cilofexor monotherapy in NASH patients does not appear to significantly mitigate hepatic fibrosis, and some patients develop moderate to severe pruritus during treatment, although perhaps less than that observed with OCA.24 A single clinical trial has been NIH funded for its use in PBC but terminated early because of the availability of alternative therapies for PBC (Clinical Trials ID: NCT02943447). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.